

## APAS® PHARMAQC SALE TO NOVACINA

Australian Contract Drug Manufacturing Organisation

**Adelaide, Australia, 29 April 2024:** Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in microbiology automation using artificial intelligence, is pleased to announce an executed contract for the sale of an APAS® Independence instrument, with APAS® PharmaQC software, to Australian-based contract development and manufacturing organisation (CDMO), NovaCina.

### Highlights:

- **Unconditional contract for the direct sale of APAS® Independence, together with the APAS® PharmaQC annual software licence and maintenance and support services over a five-year period**
- **Total cash proceeds in excess of \$0.7 million to be received over the term of the contract**
- **Delivery and installation expected June 2024 at NovaCina's aseptic manufacturing facility, located in Perth, Australia**

The Company has executed a contract for the sale of an APAS® Independence instrument, with APAS® PharmaQC software, to Perth-based CDMO company, NovaCina. The sale of the instrument will be completed with the delivery and installation of APAS® Independence scheduled for June 2024. Following the sale, Novacina will commence a validation of the instrument ahead of its routine use in the reading of culture plates collected during environmental monitoring as part of NovaCina's aseptic manufacturing processes. The APAS® instrument was sold under a 5-year agreement with a total value of over \$0.7 million (AUD), inclusive of annual software and support/maintenance fees.

The sale to NovaCina follows the Company's previously announced first sale of APAS® PharmaQC to Thermo Fisher Scientific, Inc in February 2024 ([see ASX announcement released on 22-Feb-24](#)). The two sales have been delivered approximately 6 months ahead of initial expectations and are reflective of the wider positive commercial interest generated by the Company after initiating sales and marketing activities within the biopharmaceutical industry in the second half of calendar year 2023.

Brent Barnes, CEO & Managing Director said:

*"The sale to NovaCina reflects the ongoing positive momentum and interest we have received from customers in the biopharmaceutical market. This market traction highlights the value we are providing with our APAS® product generating workflow efficiencies through AI-automation and improving the quality of their processes by increasing the data integrity and traceability of critical environmental monitoring results."*

Brett Alderson, President NovaCina said:

*"As a growing business, we strive to adopt innovation that both improves quality and traceability of our results in addition to optimising our resourcing and bottom line. The APAS® technology aligns with our paperless operations strategy and is expected to support increased scale as our business grows. We look forward to working with LBT to complete validation and expect to establish the technology for routine use in the second half of this year."*

### About NovaCina

NovaCina, owned by US Private Investment Firm, Bridgewest Group, is an Australian based CDMO that is focused on developing and producing medications of exceptional quality and safety. Based in Perth, Australia, NovaCina operate a state-of-the-art 34,000m<sup>2</sup> facility specialising in the development and manufacture of aseptic and terminally sterilised injectables. The facility, previously part of Pfizer's global manufacturing network, has been manufacturing and supplying products for over 30 years to 98 countries including the US, EU, Japan, Latin America, AFME, China and APAC. NovaCina is staffed by a dedicated, highly qualified, and long-tenured workforce of 400 staff members with an average tenure of 15 years in our facility. The facility is approved by global Health Authorities including the TGA, FDA and ANVISA.

Approved for release by the Chair of the LBT Board.

– ENDS –

**About LBT Innovations**

LBT Innovations (LBT) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

**INVESTOR ENQUIRIES**

<b>LBT Innovations</b>
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>